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1 |  INTRODUCTION
Gaucher's disease (GD) is a hereditary deficiency of the 
lysosomal enzyme glucocerebrosidase (also known as 
glucosylceramidase) causing disruption in the break-
down of the sphingolipid glucocerebroside (glucosyl-
ceramide) (Gary et al., 2018; Stirnemann et al., 2017). 
As such, it is a form of sphingolipidosis and the most 
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Abstract
Background: Understanding the basis of the phenotypic variation in Gaucher's dis-
ease (GD) has proven to be challenging for efficient treatment. The current study 
examined cardiopulmonary characteristics of patients with GD type 1.
Methods: Twenty Caucasian subjects (8/20 female) with diagnosed GD type I (GD- 
S) and 20 age- and sex- matched healthy controls (C), were assessed (mean age GD- S: 
32.6 ± 13.1 vs. C: 36.2 ± 10.6, p > .05) before the initiation of treatment. Standard 
echocardiography at rest was used to assess left ventricular ejection fraction (LVEF) 
and pulmonary artery systolic pressure (PASP). Cardiopulmonary exercise testing 
(CPET) was performed on a recumbent ergometer using a ramp protocol.
Results: LVEF was similar in both groups (GD- S: 65.1 ± 5.2% vs. C: 65.2 ± 5.2%, 
p > .05), as well as PAPS (24.1 ± 4.2 mmHg vs. C: 25.5 ± 1.3 mmHg, p > .05). GD- S 
had lower weight (p < .05) and worse CPET responses compared to C, including peak 
values of heart rate, oxygen consumption, carbondioxide production (VCO2), end- 
tidal pressure of CO2, and O2 pulse, as well as HR reserve after 3 min of recovery and 
the minute ventilation/VCO2 slope.
Conclusions: Patients with GD type I have an abnormal CPET response compared 
to healthy controls likely due to the complex pathophysiologic process in GD that 
impacts multiple systems integral to the physiologic response to exercise.
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common of the lysosomal storage diseases (Gary et al., 
2018; Stirnemann et al., 2017). The disease is caused by 
a recessive mutation in the gene located on chromosome 
1 and affects both females and males (Gary et al., 2018; 
Stirnemann et al., 2017). When glucocerebrosidase is de-
fective, glucocerebroside accumulates in mononuclear 
leucocytes, particularly in macrophages. They transform 
into so- called “Gaucher's cells” which can collect in the 
liver,  spleen,  kidneys,  lungs,  brain, and  bone marrow 
leading to malfunctions and disorders (Stirnemann et al., 
2017). Based upon neuronopathic features, there are three 
types of GD: (1) type I, non- neuronopathic (95%); (2) 
type II, acute neuronopathic; and (3) type III, chronic neu-
ronopathic (Biegstraaten et al., 2018; Elstein et al., 2018; 
Gary et al., 2018; Grabowski et al., 2015; Stirnemann 
et al., 2017). Type 1 and 3 are additionally characterized 
by direct involvement of the lungs and pulmonary vas-
culature dysfunction leading to pulmonary hypertension 
(Biegstraaten et al., 2018; Grabowski et al., 2015; Miller 
et al., 2003; Stirnemann et al., 2017). Furthermore, reports 
demonstrate cardiovascular disorders in type 3 GD, pre-
dominantly affecting the mitral and aortic valves (Gary 
et al., 2018; Kör et al., 2017). Given the pathophysiologic 
process and multisystem involvement of GD, assessment 
of potential cardiac abnormalities in other types of GD is 
highly warranted. The aim of the current study was to ex-
amine the potential utility of resting echocardiography and 
cardiopulmonary exercise testing (CPET) in the evaluation 
of patients with GD type 1.
2 |  METHOD
2.1 | Patients
We prospectively studied 20  subjects (8/20 female) di-
agnosed with type 1 GD (GD- S). The diagnosis is made 
according to clinical features, analysis of lysosomal 
betaglucocerebrosidase activity and presence of changes at 
GBA1 gene on chromosome 1q22 (MIM number 606463). 
Included subjects had the following changes: 2  subjects 
were homozygous for N370S mutation in the GBA1 gene 
locus; 18 patients had complex heterozygous mutations 
with N370S mutation at one allele and diverse changes at 
the other allele (6 patients had D409H mutation, 4 patients 
had R463H mutation, 4 patients had L444P mutation, 1 
patient had R120W mutation, 1 patient had R47X mutation, 
1 patient had deletion 1236_1317del82bp and 1 patient 
had deletion 1265_1319del55bp). Measurements were 
performed before the initiation of treatment with enzyme 
replacement therapy in the GD- S. All subjects were clini-
cally stable and did not exercise regularly.
2.2 | Blood analysis
Beta- glucosidase and chitotriosidase activity were analyzed 
from leucocytes separated from 5 ml of whole blood collected 
by venous puncture in an EDTA tube. In order to measure chi-
totriosidase activity, plasma was incubated with 4- methylum
belliferyl- β- d- NN,Nʹtriacetylchitotriose as substrate in citrate/
phosphate buffer pH 5.2, at 37℃. The result was expressed in 
µmol/L/h. Assay of acid β- glucosidase activity was performed 
by fluorogenic substrate 4- methyl- umbelliferyl- β- d- glucopyr
anoside in the presence of Triton X- 100 and pure sodium tau-
rocholate. Activity was expressed in µmol/g prot./h.
2.3 | Spirometry
Prior to the start of each CPET, subjects underwent forced 
spirometric assessments at rest using a Spirovit- SP- 10 device 
(Schiller Health Care Ltd, Switzerland) in order to calculate 
forced expiratory volume in one second (FEV1).
2.4 | CPET
Patients performed CPET on a recumbent ergometer in the 
morning, 2 hr after awakening and in a fasting state, using a 
ramp increase in work rate (WR) (American Thoracic Society; 
American College of Chest Physicians, 2003).  The test was 
terminated when the respiratory exchange ratio (RER) was 
≥1.0. Breath by breath data was collected during CPET using 
a Cardiovit CS 200 device (Schiller, Baar, Switzerland). Blood 
pressure was measured using a standard cuff sphygmomanom-
eter. Systolic (SBP) and diastolic blood pressure (DBP), heart 
rate (HR), oxygen consumption (VO2), carbondioxide output 
(VCO2), minute ventilation (VE), ventilatory equivalent for ox-
ygen (VE/VO2), O2 pulse, and the end- tidal partial pressure of 
CO2 (PETCO2) were determined at rest, peak exercise and after 
three minutes of recovery from exercise. HR reserve (HRR- 3) 
was calculated as the difference between HR peak and HR after 
three minutes of recovery from CPET. Peak VO2 and the peak 
RER was the average of last 15s of CPET. VE and VCO2 val-
ues, acquired from the initiation of exercise to peak were input 
into spreadsheet software (Microsoft Excel, Microsoft Corp., 
Bellevue, WA) to calculate the VE/VCO2  slope via least 
squares linear regression (y = mx + b, m = slope).
2.5 | Echocardiography
Standard B- mode echocardiography at rest was performed 
using Vivid 9 ultrasound device (BTO6, 1.5– 3.6  MHz; 
GE Healthcare Technologies, Waukesha, WI, USA) to as-
sess left ventricular ejection fraction (LVEF), according to 
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recommended criteria (Lang et al., 2015). Pulmonary artery 
systolic pressure (PASP) was estimated by Doppler echocar-
diography from the systolic right ventricular to right atrial 
pressure gradient using the modified Bernoulli equation. 
Right atrial pressure (assessed jugular venous pressure) was 
added to the calculated gradient to yield PASP (Rudski et al., 
2010).
2.6 | Statistics
Results are expressed by mean and standard deviation. 
Correlations between variables were performed by Pearson`s 
correlation test and Spearman's rank correlation test. The dif-
ferences between parameters were assessed by the Student's 
t- test. Binary logistic regression analysis was performed to 
identify the best model to predict probability of GD on CPET 
studies. Hierarchical models were defined considering the 
statistical significance and clinical relevance of independent 
variables, taking into consideration principal effects and sec-
ond level interactions in each model. Statistical tests were 
considered significant when a p- value was <.05. The SPSS 
software package (SPSS version 17.0, SPSS Inc., Chicago, 
Illinois, USA) was used for all statistical analyses.
3 |  RESULTS
All subjects diagnosed with GD demonstrated hepatomegaly; 
16 patients had splenomegaly, whereas 4 of them underwent 
splenectomy. Of 20 patients, 15 had thrombocytopenia and 
8 had osteopenia. Hemoglobin levels were normal in all pa-
tients. Subjects in the GD- S and C demonstrated a similar age 
and height; GD- S had a lower weight and BMI, as shown in 
Table 1. FEV1, HR at rest, and SBP and DBP in all phases 
of CPET were normal in both groups and of similar values 
(p > .05). HR peak, HRR- 3, O2 pulse peak, as well as VO2, 
VCO2, and PETCO2 at all phases of CPET were lower while 
the VE/VCO2 slope was higher in GD- S compared to control.
Significant correlations between beta- glucosidase and 
chitotriosidase activity with cardiopulmonary and echocar-
diographic parameters in GD- S were not found, as shown in 
Table 2.
4 |  DISCUSSION
The major finding of this study is that patients with GD type 1 
demonstrated normal echocardiographic, but a worse overall 
CPET response compared to controls, including the chrono-
tropic response, ventilatory efficiency, HRR, O2 pulse, VO2, 
VCO2, and PETCO2. Given the clinical importance of as-
sessing cardiorespiratory fitness, now viewed as a vital sign 
(Ross et al., 2016), our findings potentially have important 
clinical implications for this patient population.
GD type 1 encompasses complex pathophysiology 
leading to clinical findings that portend a poor prognosis 
(Biegstraaten et al., 2018). Understanding the basis for the 
clinical variation in GD type I is rather challenging, as nei-
ther the quantity of lipid stored nor the amount of residual 
enzymatic activity has correlated well with the patient's phe-
notype and responses to treatment (Biegstraaten et al., 2018). 
GD type 1 does not carry any neuronopathic features and is 
characterized by bone disease, hepatosplenomegaly, anemia 
and thrombocytopenia, lung,  and pulmonary vasculature 
dysfunction (Biegstraaten et al., 2018). Cardiopulmonary 
complications have been rarely described in GD type I, but 
appear to encompass restrictive cardiomyopathy, pulmonary 
hypertension, calcifications of the valves and mitral regurgi-
tation (Roghi et al., 2017). Our results did not show any struc-
tural cardiac changes or increased PASP in GD- S, suggesting 
that there were no echocardiographic signs of pulmonary 
hypertension at rest. Moreover, ventilatory function at rest 
and during effort appeared to be normal. However, lower val-
ues of PETCO2 during CPET and a higher VE/VCO2 slope 
in GD- S are suggestive of the potential for vascular distur-
bances and impaired gas exchange at the level of alveolocap-
illary membrane characteristic of pulmonary hypertension 
(American Thoracic Society; American College of Chest 
Physicians, 2003). The chronotropic response and HRR- 3 
were also worse in GD- S, demonstrating possible autonomic 
dysfunction in these patients (Kawasaki et al., 2010). A lower 
peak O2 pulse in the GD- S group, is suggestive of an inability 
to increase cardiac output during exercise, which is common 
for all heart failure phenotypes, and particularly useful for the 
detection of heart failure with preserved EF (Popovic et al., 
2018). Furthermore, decreased peak VO2 in GD- S demon-
strates a systemic impairment (cardiopulmonary, skeletal 
muscle, and autonomic dysfunction) due to combination of 
complex pathophysiological mechanisms in GD type I that 
may have prognostic value (American Thoracic Society; 
American College of Chest Physicians, 2003; Lin and Radin, 
1973). Finally, due to clinical features, deconditioning is not 
excluded as contributing mechanism for VO2 decrease. The 
lower VCO2 output is suggestive of possible alternate meta-
bolic paths in ceramidase metabolism that may characterize 
patients with GD giving the hope that CPET measurements 
can be useful tool to assess the intensity of metabolic de-
rangements in accordance with the disease activity and re-
sponses to therapy (Guazzi et al., 2016). Additional finding 
of the current study was lower BMI in GD- S, which was in 
accordance to previous reports demonstrating lower prev-
alence of overweight in untreated GD than in the general 
population. This finding was explained by metabolic ab-
normalities such as high resting energy expenditure in these 
patients (Langeveld et al., 2008). In support, treatment with 
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enzyme replacement therapy leads to a decrease in resting 
energy expenditure, increase of body weight, and possible in-
sulin resistance. These metabolic alterations may contribute 
to overall functional capacity, as well.
The lack of significant correlations of chitotriosidase 
and beta- glucosidase activity with echocardiographic and 
CPET findings suggest that these blood markers are not 
sufficient for overall assessment and follow up of patients 
with GD.
Altogether, in the current study CPET was found to be 
informative in terms of revelation of overall body impair-
ment in patients diagnosed with GD. It gives an insight in 
particular clinical aspects of this rare disease, enabling early 
detection of characteristic features. CPET allows detection 
of incipient changes in alveocapillary membrane and pul-
monary hypertension even before resting echocardiogra-
phy. It also allows diagnosis of heart failure before manifest 
reduction of ejection fraction. It gives an insight in meta-
bolic and hematologic changes specific to GD. Thus, early 
CPET is highly recommendable in patients diagnosed with 
GD, both for pro- diagnostic reasons and for gauging effects 
of therapy.
4.1 | Limitation
The small sample size was a key limitation to the pre-
sent study. As such, future studies should be conducted 
in larger cohorts allowing for the prognostic assessment 
of CPET measures in patients with GD. Of note, the cur-
rent study was performed in native patients, before spe-
cific treatment. Further studies should emphasize CPET 
changes due to therapeutic interventions in patients diag-
nosed with GD.
GD- S (n = 20) C (n = 20) p
Age (years) 32.6 ± 13.1 36.2 ± 10.6 .366
Height (m) 1.7 ± 0.1 1.8 ± 0.1 .302
Weight (kg) 65.2 ± 12.1 75.9 ± 13.1 .014
BMI (kg/m2) 22.1 ± 3.1 24.6 ± 3.0 .015
PAPS (mmHg) 24.1 ± 4.2 25.5 ± 1.3 .229
LVEF (%) 65.1 ± 5.2 65.2 ± 5.2 .991
FEV1 (L) 3.4 ± 0.8 3.8 ± 0.7 .115
RER peak 1.05 ± 0.07 1.07 ± 0.03 .301
VO2 rest (ml/min/kg) 3.5 ± 1.9 3.9 ± 0.5 .326
VO2 peak (ml/min/kg) 24.8 ± 7.2 31.6 ± 9.3 .002
VO2 recovery (ml/min/kg) 6.7 ± 2.5 7.8 ± 2.5 .188
VCO2 rest (ml/min) 203.5 ± 114.0 255.0 ± 56.9 .092
VCO2 peak (ml/min) 1737.0 ± 678.8 2750.6 ± 1083.5 .001
VCO2 recovery (ml/min) 600.0 ± 226.6 872.7 ± 404.3 .013
PETCO2 rest (mmHg) 33.6 ± 3.6 34.4 ± 3.6 .497
PETCO2 peak (mmHg) 41.8 ± 5.0 46.4 ± 4.4 .005
HR rest (beats/min) 74 ± 11 69 ± 16 .253
HR peak (beats/min) 149 ± 18 161 ± 18 .045
HRR- 3 (beats/min) 51 ± 10 63 ± 12 .002
O2 pulse peak 11.0 ± 3.7 15 ± 4.9 .007
VE/VO2 peak 26.4 ± 3.8 26.8 ± 3.6 .411
VE/VCO2 slope 30.3 ± 0.1 22.7 ± 2.1 <.0001
Chitotriosidase (µmol/L/h) 8471.4 ± 6423.7 – 
Beta- glucosidase (µmol/g/h) 1.7 ± 0.7 – 
Note: The values are expressed as mean ± SD.
Abbreviations: BMI, body mass index; C, healthy control population matched by sex and age; FEV1, forced 
expiratory volume in the 1st second; GD- S, subjects with Gaucher's disease; HR, heart rate; HRR- 3, heart rate 
reserve after three minutes of recovery; LVEF, left ventricular ejection fraction; O2 pulse, oxygen pulse; PAPS, 
systolic pulmonary artery pressure; PETCO2, end- tidal partial pressure of carbondioxide; RER, respiratory 
exchange ratio; VE/VO2, ventilatory equivalent for oxygen; VO2, oxygen consumption; VCO2, carbondioxide 
output; VE, minute ventilation.
T A B L E  1  Clinical, echocardiographic, 
and CPET parameters in subjects with 
Gaucher's disease and healthy control 
population
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5 |  CONCLUSION
The results of the present study demonstrate that patients 
with GD type I have an abnormal CPET response compared 
to healthy controls. These findings are likely due to the com-
plex pathophysiologic process in GD that impacts multiple 
systems integral to the physiologic response to exercise. 
Future research should be conducted to further determine the 
clinical value of CPET in patients with GD.
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